Profile data is unavailable for this security.
About the company
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
- Revenue in USD (TTM)7.52m
- Net income in USD-33.46m
- Incorporated2011
- Employees30.00
- LocationClearside Biomedical Inc900 North Point Parkway, Suite 200ALPHARETTA 30005United StatesUSA
- Phone+1 (678) 270-3631
- Fax+1 (678) 270-4033
- Websitehttps://clearsidebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aileron Therapeutics Inc | 0.00 | -25.22m | 77.78m | 15.00 | -- | 1.39 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 77.95m | 89.00 | -- | 0.5706 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 78.30m | 228.00 | -- | 0.2906 | -- | 1.40 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 79.12m | 12.00 | -- | 9.63 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 79.46m | 50.00 | -- | 0.6163 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 79.67m | 72.00 | -- | 0.4445 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 79.79m | 35.00 | -- | -- | -- | 42.53 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 80.42m | 16.00 | -- | 24.78 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 81.18m | 22.00 | -- | 0.9475 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| CytomX Therapeutics Inc | 126.62m | 13.83m | 81.39m | 120.00 | 6.21 | -- | 5.19 | 0.6428 | 0.1675 | 0.1675 | 1.52 | -0.2998 | 0.7031 | -- | 43.88 | 1,055,142.00 | 7.68 | -21.53 | 29.38 | -32.32 | -- | -- | 10.92 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 81.41m | 66.00 | -- | -- | -- | 21.89 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Clearside Biomedical Inc | 7.52m | -33.46m | 81.47m | 30.00 | -- | -- | -- | 10.83 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 84.09m | 41.00 | -- | 0.7796 | -- | 86.65 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Agenus Inc | 159.63m | -223.67m | 84.13m | 389.00 | -- | -- | -- | 0.527 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Allovir Inc | 0.00 | -140.34m | 85.38m | 112.00 | -- | 0.7084 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Clearside Biomedical Inc's reporting currency: US Dollar USD
15.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.82m | 3.78% |
| Armistice Capital LLCas of 30 Jun 2024 | 2.14m | 2.86% |
| Carmignac Gestion SAas of 30 Jun 2024 | 2.13m | 2.85% |
| White Creek Capital LLPas of 30 Sep 2024 | 1.51m | 2.02% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 783.35k | 1.05% |
| Geode Capital Management LLCas of 30 Jun 2024 | 672.30k | 0.90% |
| Carmignac UK Ltd.as of 28 Mar 2024 | 624.40k | 0.84% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 582.69k | 0.78% |
| Assenagon Asset Management SA (Germany)as of 30 Sep 2024 | 257.10k | 0.34% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 205.16k | 0.27% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
